Navigation Links
Promising medication counteracts constipation caused by opioid painkillers
Date:7/16/2014

Opioids strong morphine-based painkillers are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. A new drug, called naloxegol, could bring relief. In stage 3 trials reported in the New England Journal of Medicine, KU Leuven and international researchers provide new evidence that the drug relieves constipation without dulling opioids' pain-relieving effects.

Up until a decade ago, physicians rarely prescribed opioids, reserving them primarily for the terminally sick. Today, opioid-based drugs have proliferated thanks to their 'user-friendliness' and effectiveness. Millions of patients take opioids on a daily basis to manage lower back pain and chronic joint problems. Opioids also play a critical role in pain management regimes for cancer patients.

However, opioids have a number of side effects, including nausea, vomiting and notoriously constipation. Opioids block pain by binding to 'mu-receptors' in the brain. But they also bind to mu-receptors in the bowels, and this causes constipation.

Some sixty percent of patients that take opioid pain relievers experience constipation. For some, the bother is so great that they choose to stop taking the drug.

A newly developed opioid antagonist called naloxegol may offer relief. Stage 3 testing by an international team of researchers led by Belgian gastroenterologist Jan Tack (University Hospitals Leuven) confirms the drug's efficacy.

Naloxegol is based on the same active molecule as naloxone, a drug developed in the 1960s to counter the effects of opioid overdose. Naloxone is commonly used to wake patients from opioid-induced anesthesia after surgery.

To arrive at naloxegol, the researchers modified the molecular structure of naloxone. The result is an orally administered, once-a-day pill for patients experiencing opioid-induced constipation.

The researchers tested the pill's efficacy in two phase 3 studies with promising results. Naloxegol was shown to maintain opioids' pain-killing effect in the brain and block their effects in the bowels. Bowel function in all of the 1,400 test subjects returned to normal and accompanying stomach pain and other discomforts decreased. No patients experienced a diminished pain-relieving effect as a result of the drug.

While the studies addressed in the paper focused on patients taking opioids for non-cancer pain such as back pain and other musculoskeletal ailments, similar studies are now underway to examine the effect of naloxegol in patients with chronic cancer-related pain.

Final regulatory approval for the drug is pending in the United States and Europe.


'/>"/>

Contact: Jan Tack
jan.tack@med.kuleuven.be
321-634-4225
KU Leuven
Source:Eurekalert

Related medicine news :

1. New therapy for pancreatic cancer patients shows promising results
2. Immune therapy for advanced bladder cancer yields promising results
3. Experimental trial represents promising step toward universal antidote for snakebite
4. Sleep researchers at SRI International identify promising new treatment for narcolepsy
5. Researchers present findings on promising biomarker for esophageal cancer
6. Vibrating capsule shows promising results in treating chronic constipation
7. Danish nasal filter looks promising for allergy sufferers
8. Scientists explore promising new option for first line of attack in lymphoma
9. GW researcher finds gene therapy a promising tool for cardiac regeneration
10. NUS researchers make new discovery of protein as a promising target for treatment of ATC
11. LA BioMed researchers report on promising new therapy for devastating genetic disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... The ... “Humans With Vaginas.” The goal is to ignite conversation via social media and ... products. The brand has declared September “Humans with Vaginas” month, releasing a video ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... Houston, ... entire team took Friday, September 8, and Monday, September 11, off work and rolled ... Second Baptist Church before heading to local homes to start the process of rebuilding. ...
(Date:9/20/2017)... ... 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning ... author, Jeanine Liston, a busy mother of five who used her time waiting for children ... book for over twenty years. It was a way to give some meaning to ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, M.D., ... Professional Member in recognition of his contributions to the ... as a Nephrologist at the practice of Kidney and ... kidney care and hypertension solutions. He has worked in ... of career experience, as well as expertise in kidneys, ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
Breaking Medicine Technology: